More seizure-free days may be on the horizon
The EMERALD study is evaluating a potential new treatment to reduce seizures caused by Development and Epileptic Encephalopathies (DEEs).
About the EMERALD Study
Purpose
To understand how safe and effective relutrigine is in reducing seizures
Duration
Up to 24 weeks in the initial study, with the opportunity to continue to stay on treatment for an additional 32 weeks in an open-label extension
At home
United States, South America, Europe, Australia
Choose between at-home, in-clinic, or combined participation
About Relutrigine
Relutrigine is an investigational medicine that can be taken orally or administered through a G/J tube. Relutrigine is designed to regulate sodium flow in brain cells by targeting overactive sodium channels that cause seizures; therefore, potentially offering better seizure control with fewer side effects. Relutrigine has been designed to maximize its effects against overactive sodium channels that are believed to cause seizure activity while minimizing the blocking of normal activity needed for healthy brain function.
You may be able to participate if you
-
Are 2 through 65 years old - Have received a diagnosis of a DEE caused by genetic mutation and/or syndrome diagnosis
- Have at least 4 motor seizures (seizures that involve movement) in the 4 weeks prior to screening
Why participate?
- The flexibility to participate at-home, in-clinic at a study site, or a combination of both
- If your family chooses to attend in-clinic study visits, all expenses for travel, lodging, meals and any other costs associated with study participation will be paid for by the sponsor
- All participants will receive relutrigine at some point during the study
- Option to continue to stay on relutrigine for an additional 32 weeks after the initial study is completed
- Your loved one may be able to continue on relutrigine after the completion of trial participation through an expanded access program if he/she showed clear benefits beyond previous therapeutic treatments
